VCBeat Health Contact Us
Home Innovent Biologics Acquires 18% Stake in IASO Bio as IASO Secures Full Global Rights to Fucaso® (Equecabtagene Autoleucel)

Innovent Biologics Acquires 18% Stake in IASO Bio as IASO Secures Full Global Rights to Fucaso® (Equecabtagene Autoleucel)

Jul 06, 2024 11:18 CST Updated 11:18
Innovent

High-end Biologics Developer

IASO Biotechnology

Cancer Treatment New Drug Developer